Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant anti-EGFR chimeric monoclonal antibody
- Development stage
- Phase 3
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Recombinant anti-EGFR chimeric monoclonal antibody is a target-specific generic descriptor referring to several human-murine chimeric monoclonal antibodies directed against the epidermal growth factor receptor (EGFR). In China, this term is commonly used in clinical trial registries to describe cetuximab biosimilars or biobetters under development by various pharmaceutical companies. Key examples of assets developed under this description include HLX05/HLX05-N (developed by Henlius/Fosun), A140 (developed by Kelun-Biotech), and CMAB009 (Enlituo, developed by Mabpharm/Zhangjiang Biotech and commercialized by Simcere). These antibodies bind to EGFR, inhibiting downstream signaling pathways and mediating antibody-dependent cellular cytotoxicity (ADCC) to treat EGFR-expressing malignancies such as metastatic colorectal cancer (mCRC) and head and neck squamous cell carcinoma (HNSCC).
- Brand names
- DatailaiEnlituo
- Other names
- cetuximab betacetuximab biosimilarrecombinant anti-EGFR human-mouse chimeric monoclonal antibodyrecombinant anti-EGFR human/mouse chimeric monoclonal antibodyrecombinant anti-EGFR human/murine chimeric monoclonal antibody
02
Targets
EGFRvIII (Epidermal growth factor receptor variant III)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on recombinant anti-EGFR chimeric monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant anti-EGFR chimeric monoclonal antibody.